Pharma

Your Article Summary

See Latest Articles

New Long-Term Data Provide Guidance on the Use of Sustiva(R) (Efavirenz) in HIV-Treatment-Naive Patients
Bristol Myers-Squibb Company, 03/27/09

Bristol-Myers Squibb Company announced that SUSTIVA has received approval from the U.S. Food and Drug Administration (FDA) to include new long-term virologic and clinical data from BMS Study 006 in its prescribing information. The new data demonstrate the long-term durability of virologic response in people living with HIV-1 who are naive to protease inhibitors, lamivudine (3TC) and non-nucleoside reverse transcriptase inhibitors (NNRTI) through more than three years of treatment on a combination regimen containing SUSTIVA.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Multaq Approved in the European Union for Patients with Atrial Fibrillation
Sanofi-aventis, 12/01/09

FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS
BioMarin, 12/01/09

Novartis gains rights to two oral targeted investigational therapies focusing on patients with life-threatening blood disorders and cancers
Novartis, 11/30/09

 See all of Drug/Product Approvals